Partial protection against acute renal failure by Efamol.
Papanikolaou
N
N
Institut Franco-Hellénique de Recherches Biomédicales, Hôpital Général d'Agrinion, Grèce, France.
Darlametsos
J
J
Hatziantoniou
C
C
Gkika
E
E
Lefkos
N
N
Stewart
C
C
Horrobin
D
D
Giannoulis
K
K
Bariety
J
J
D015121:6-Ketoprostaglandin F1 alpha / Q000652:urine; D058186:Acute Kidney Injury / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control*; D000818:Animals; D005228:Fatty Acids, Essential / Q000494:pharmacology*; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D000960:Hypolipidemic Agents / Q000494:pharmacology; D008041:Linoleic Acids; D008627:Mercuric Chloride / Q000633:toxicity; D031665:Oenothera biennis; D010938:Plant Oils; D011458:Prostaglandins E / Q000652:urine; D051381:Rats; D011914:Rats, Inbred BN; D013929:Thromboxane B2 / Q000652:urine; D017965:gamma-Linolenic Acid
D005228:Fatty Acids, Essential; D000960:Hypolipidemic Agents; D008041:Linoleic Acids; D010938:Plant Oils; D011458:Prostaglandins E; C028498:evening primrose oil; D008627:Mercuric Chloride; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D017965:gamma-Linolenic Acid